H. Lind

FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.

S. Dower, A. Tjärnlund-Wolf, T. Weimer, 2020, Blood advances.

Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo.

Adriana Baz Morelli, S. Dower, M. Hardy, 2022, The Biochemical journal.

Modulation of Extravascular Binding of Recombinant Factor IX Impacts the Duration of Efficacy in Mouse Models

E. Herzog, M. Nolte, M. Bacher, 2022, Thrombosis and Haemostasis.